XOMA Royalty has developed several unique functional antibody antagonists targeting PTH1R, a G-protein-coupled receptor involved in the regulation of calcium metabolism.
These antibodies have shown promising efficacy in in vivo studies and could potentially address high unmet medical needs, including hyperparathyroidisms and humoral hypercalcemia of malignancy (HHM). HHM is present in many advanced cancers and is caused by high serum calcium due to increased levels of the PTH1R ligand PTH-related peptide (PTHrP). Current HHM treatments often fall short, and many cancer patients die from ‘metabolic death’. New PTH1R antibodies could be beneficial for the treatment of HHM.
